Nakamura Akihide, Yamaguchi Tomohiro, Ito Ryugo, Kawakami Keiki
Division of Hematology and Oncology, Suzuka General Hospital.
Department of Microbiology and Molecular Genetics, Mie University Graduate School of Medicine.
Rinsho Ketsueki. 2020;61(11):1600-1604. doi: 10.11406/rinketsu.61.1600.
A 59-year-old woman was referred by her family doctor to our hospital owing to anemia, nausea, and malaise. She was diagnosed with primary plasma cell leukemia based on her laboratory and morphologic findings. She was treated with high dose of dexamethasone; cyclophosphamide, bortezomib, and dexamethasone; and carfilzomib, lenalidomide, and dexamethasone. She achieved partial treatment response. We switched her treatment to daratumumab, lenalidomide, and dexamethasone (DRd) owing to progression of peripheral neuropathy. Bone marrow examination performed after 15 courses of DRd revealed minimal residual disease-negative status. Sequential multidrug combination chemotherapies may be related to long-term successful disease control.
一名59岁女性因贫血、恶心和不适被其家庭医生转诊至我院。根据实验室检查和形态学结果，她被诊断为原发性浆细胞白血病。她接受了高剂量地塞米松、环磷酰胺、硼替佐米和地塞米松，以及卡非佐米、来那度胺和地塞米松治疗。她获得了部分治疗反应。由于周围神经病变进展，我们将她的治疗方案改为达雷妥尤单抗、来那度胺和地塞米松（DRd）。在接受15个疗程的DRd治疗后进行的骨髓检查显示微小残留病阴性状态。序贯多药联合化疗可能与长期成功控制疾病有关。
